Bamlanivimab must be administered within 10 days of symptom onset (preferably <5 days)
and as soon as possible after a positive viral test for SARS-CoV-2.
Bamlanivimab must be administered within 10 days of symptom onset (preferably <5 days)
and as soon as possible after a positive viral test for SARS-CoV-2.
Patient Qualification
Patient must have a positive COVID-19 test.
- The patient must MEET AT LEAST ONE criteria below for being at high risk of developing severe COVID:
- BMI greater than or equal to 35
- Chronic kidney disease (CKD)
- Diabetes
- Immunosuppressive disease
- Currently receiving immunosuppressive treatment
- Age 65 years old or older
- Age 55 years old or older with cardiovascular disease
- Age 55 years old or older with hypertension
- Age 55 years old or older with chronic obstructive pulmonary disease
- Age 12-17 years old with BMI greater than or equal to the 85th percentile for age/gender
- Age 12-17 years old with Sickle cell disease
- Age 12-17 years old with Congenital or acquired heart disease
- Age 12-17 years old with Neurodevelopmental disorders
- Age 12-17 years old with Medical-related technology dependence (tracheostomy, gastrostomy,
positive pressure ventilation, )
- Age 12-17 years old with Asthma
- Age 12-17 years old with Reactive airway or other chronic respiratory disease requiring
treatment
- The patient DOES NOT MEET any of the exclusion criteria/limitations of authorized use under the Bamlanivimab EUA per below:
- Hospitalized due to COVID-19
- Require oxygen therapy due to COVID-19
- Require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic
oxygen therapy due to underlying non-COVID related comorbidity
- This patient is at least 12 years old and weighs at least 40 kg with a positive result
for SARS- CoV-2 and meets the criteria for being at high risk of developing severe
COVID-19 as documented above.
How to Get Started
- Patient must meet the inclusion criteria
- Patient must have the following information readily available
- Patient Name
- DOB
- Patient Mobile # (to initiate Virtual Care visit)
- Patient Email
- Date of + COVID-19 Result
- Date of Symptom Onset
- Patient will be screened via AU Health Virtual Care platform to verify infusion appropriateness,
discuss the risks/benefits of the infusion and provide next steps
- A health care provider can make also make a referral by calling 706-721-9449.
Provider Referral Form
What to Expect
Detailed instructions for infusion treatment will be provided upon scheduling.
Benefit of treatment has not been observed in patients hospitalized due to COVID-19.
Monoclonal antibodies, such as Bamlanivimab, may be associated with worse clinical
outcomes when administered to hospitalized patients with COVID-19 requiring high flow
oxygen or mechanical ventilation